ROKIT Healthcare shares two-year skin cancer reconstruction data at EWMA 2026, signaling a wider future for regenerative longevity medicine.
Skin cancer is often described as one of the “easier” cancers to treat. In many cases, doctors can remove the tumor surgically, stitch the wound and send the patient home the same day. However, that description leaves out what happens after.
For many patients, especially older adults, the visible and physical aftermath can linger long after the cancer is gone: tight skin, numbness, scarring or the quiet psychological discomfort of seeing your body permanently altered in the mirror. A successful surgery, in other words, does not always feel like full recovery.
That tension is at the core of this year’s European Wound Management Association (EWMA) 2026 conference in Bremen, Germany, where South Korean biotech company ROKIT Healthcare presented new long-term data on its AI-driven regenerative platform for skin cancer reconstruction.
The company shared one- to two-year follow-up results for patients treated after skin cancer removal using bioprinted regenerative tissue made from their own fat cells. According to the company, no recurrence was observed during the follow-up period, while patients also experienced functional recovery, sensory restoration, aesthetic improvement and minimal scarring [1].
For a field that has long treated reconstruction as secondary to survival, the presentation hinted at a future in which medicine may aim not only to save tissue but also to restore it as naturally as possible.
The technical language around regenerative medicine can sometimes sound intimidating: “AI bioprinting,” “autologous adipose tissue,” “precision reconstruction.” However, stripped down to its essentials, the idea is direct. Instead of patching a wound with synthetic material or borrowing large sections of skin from elsewhere in the body, ROKIT Healthcare’s platform uses a patient’s own fat tissue as the raw material for repair. AI software helps scan and map the damaged area, almost like creating a custom blueprint before reconstruction begins.
Traditional skin grafts can save lives, but they may also leave scars, reduced sensation or limited mobility depending on the location of the surgery. Regenerative approaches are trying to move medicine closer to something more restorative, helping the body rebuild in a way that feels more like itself again.
ROKIT Healthcare presented the findings under the title, “Autologous adipose tissue regeneration using AI bioprinting following skin cancer resection: 1–2 year long-term follow-up outcomes,” where the company reported:
- 0% recurrence during the follow-up period of up to two years
- restored function and appearance in treated areas
- sensory recovery with minimal scarring
Of course, early clinical data should always be viewed carefully. Two-year follow-up results are promising, but they are not the same as the broad clinical consensus. Larger studies and expanded trials will still be needed before technologies like this become standard practice across healthcare systems.
Still, the durability of the outcomes is notable. In regenerative medicine, short-term success is common. Long-term stability is harder to prove.
Europe is watching closely as it has one of the world’s highest incidences of non-melanoma skin cancer, with the regional treatment market projected to reach around $890 million (KRW 1.3 trillion). As populations age and healthcare systems face mounting pressure, hospitals are increasingly looking for treatments that improve outcomes without dramatically increasing costs.
That is part of the pitch behind regenerative platforms like ROKIT’s. Rather than relying on expensive artificial skin products or multiple reconstructive surgeries, the company says its platform creates personalized regenerative patches directly on-site using the patient’s own tissue. In theory, that could reduce recovery complications while easing some of the financial burden on healthcare providers.
At EWMA 2026, the company demonstrated the platform live, from wound scanning to producing customized regenerative patches, while also holding meetings with hospitals and medical device distributors across Germany and France.
ROKIT Healthcare says it plans to secure preliminary agreements with three partners across Europe and the Middle East during the first half of the year.
The longevity angle is becoming clearer. ROKIT Healthcare originally developed its platform for diabetic foot ulcers, a type of chronic wound that can lead to infection and amputation if left untreated. Expanding the same technology into skin cancer reconstruction suggests that regenerative medicine is beginning to evolve into a broader infrastructure platform – one that could eventually touch multiple organs and age-related conditions.
Longevity.Technology: The company has already pointed toward future applications involving cartilage and kidney regeneration. That matters because longevity science is increasingly shifting away from the fantasy of simply “living longer.” The more serious conversation now revolves around resilience: preserving mobility, function, appearance, independence and dignity as people age.
Regenerative medicine sits directly inside that conversation. Healing a wound is one thing. Restoring sensation, minimizing scars and helping tissue behave more naturally again touches something deeper about how people experience aging itself.
“The two-year long-term follow-up results confirm that ROKIT Healthcare’s technology goes beyond temporary wound healing – demonstrating its value and technical prowess in the precision medicine field of cancer reconstruction,” a ROKIT Healthcare spokesperson said.
Whether regenerative bioprinting ultimately becomes mainstream remains to be seen. But at EWMA 2026, the industry’s direction was hard to ignore. The longevity sector may start learning how to rebuild the body after damage has already occurred.
Photograph courtesy of ROKIT Healthcare
[1] https://rokithealthcare.com/en/newsroom/news/news?id=147
